`
`
`
`Paper No. ___
`
`Date Filed: May 3, 2017
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`________________
`
`MYLAN PHARMACEUTICALS INC., ACTAVIS LABORATORIES FL, INC.,
`AMNEAL PHARMACEUTICALS LLC, AMNEAL PHARMACEUTICALS OF
`NEW YORK, LLC, DR. REDDY’S LABORATORIES, INC., DR. REDDY’S
`LABORATORIES, LTD., SUN PHARMACEUTICALS INDUSTRIES, LTD.,
`SUN PHARMACEUTICALS INDUSTRIES, INC., TEVA
`PHARMACEUTICALS USA, INC., WEST-WARD PHARMACEUTICAL
`CORP., and HIKMA PHARMACEUTICALS, LLC,
`Petitioner,
`
`v.
`
`JANSSEN ONCOLOGY, INC.,
`Patent Owner.
`
`________________
`Case IPR2016-013321
`Patent 8,822,438 B2
`________________
`
`
`PATENT OWNER’S REQUEST FOR ORAL ARGUMENT
`
`
`
`1 Case IPR2017-00853 has been joined with this proceeding.
`
`
`
`IPR2016-01332
`U.S. Patent 8,822,438
`
`
`
`Pursuant to 37 C.F.R. § 42.70, Patent Owner Janssen Oncology, Inc. hereby
`
`respectfully requests oral argument in this proceeding. In accordance with 37
`
`C.F.R. § 42.70(a), Patent Owner specifies the following issues to be argued:
`
`1. Patentability of claims 1-20 of U.S. Patent 8,822,438, including evidence
`
`related to objective indicia of nonobviousness;
`
`2. Patent Owner’s motion to exclude and any motion to exclude filed by
`
`Petitioners;
`
`3. Patent Owner’s motion for observations on cross-examination;
`
`4. Issues related to portions of Petitioners’ Reply that Patent Owner believes
`
`constitute new arguments;
`
`5. Any issues specified by Petitioners in their request for oral argument or
`
`raised by Petitioners during oral argument; and
`
`6. Any other issues that the Board deems necessary for issuing a final written
`
`decision.
`
`
`
`In light of the extensive record developed in this proceeding, including the
`
`submission of expert declarations from eight different declarants (four per side),
`
`Patent Owner respectfully requests a minimum of 45 minutes of oral argument to
`
`address the issues outlined above.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`1
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`
`
`/Dianne B. Elderkin/
`Dianne B. Elderkin (Reg. No. 28,598)
`delderkin@akingump.com
`Barbara L. Mullin (Reg. No. 38,250)
`bmullin@akingump.com
`Ruben H. Munoz (Reg. No. 66,998)
`rmunoz@akingump.com
`AKIN GUMP STRAUSS HAUER &
`FELD LLP
`Two Commerce Square
`2001 Market Street, Suite 4100
`Philadelphia, PA 19103
`Tel: (215) 965-1200
`Fax: (215) 965-1210
`
`David T. Pritikin (pro hac vice)
`Bindu Donovan (pro hac vice)
`Paul J. Zegger (Reg. No. 33,821)
`Todd L. Krause (Reg. No. 48,860)
`Alyssa B. Monsen (pro hac vice)
`SIDLEY AUSTIN LLP
`787 Seventh Avenue
`New York, NY 10019
`Tel.: (212) 839-5300
`Fax: (212) 839-5599
`ZytigaIPRTeam@sidley.com
`
`Counsel for Patent Owner
`
`
`
`2
`
`IPR2016-01332
`U.S. Patent 8,822,438
`
`
`
`Dated: May 3, 2017
`
`
`
`
`
`
`
`IPR2016-01332
`U.S. Patent 8,822,438
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing Patent
`
`Owner’s Request for Oral Argument was served on counsel of record on May 3,
`
`2017 by filing this document through the End-to-End System, as well as delivering
`
`a copy via electronic mail to counsel of record for the Petitioners at the following
`
`addresses:
`
`Brandon M. White – bmwhite@perkinscoie.com
`Crystal R. Canterbury – ccanterbury@perkinscoie.com
`Bryan D. Beel – bbeel@perkinscoie.com
`Shannon Bloodworth – sbloodworth@perkinscoie.com
`Emily J. Greb – egreb@perkinscoie.com
`Robert D. Swanson – rswanson@perkinscoie.com
`
`Samuel S. Park – spark@winston.com
`Ryan B. Hauer – rhauer@winston.com
`Jovial Wong – jwong@winston.com
`
`
`
`Date: May 3, 2017
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`
`/Dianne B. Elderkin/
`Dianne B. Elderkin
`Registration No. 28,598
`Counsel for Patent Owner
`
`
`
`3
`
`